Pharma as an essential sector under NIS2
The NIS2 directive classifies pharmaceutical manufacturers as essential entities. This covers companies producing active pharmaceutical ingredients (API), finished medicinal products, medical devices, and companies conducting clinical trials. Threshold: employment above 50 people or turnover above EUR 10M. In practice, this covers virtually all significant players in the European pharmaceutical market — from multinationals to mid-size generic companies.
Key NIS2 requirements for pharma
Risk management (Art. 21)
Pharmaceutical companies must implement comprehensive cybersecurity risk management covering:
- Risk analysis including OT production systems
- Supply chain security (API suppliers, CMOs, CROs)
- Laboratory system vulnerability management (LIMS, ELN)
- Access control for clinical trial data
Incident reporting (Art. 23)
- 24 hours — initial CSIRT notification
- 72 hours — detailed report with impact assessment
- 1 month — final report with root cause analysis
Management accountability (Art. 20)
Pharmaceutical company management bears personal responsibility for cybersecurity oversight. Management training required.
Supply chain security (Art. 21.2d)
Particularly important in pharma — verifying cybersecurity of API suppliers, packaging companies, distributors, and logistics partners.
Penalties for non-compliance
For essential entities (including pharma): up to EUR 10M or 2% of annual turnover — whichever is higher. For global pharmaceutical corporations, fines can reach tens of millions of euros. Additionally, management may face bans from holding executive positions.
NIS2 implementation plan for a pharma company
Phase 1 (month 1-2): Audit and gap analysis
- Inventory of critical systems (OT, LIMS, ELN, ERP)
- Assessment of current cybersecurity state vs NIS2 requirements
- Supply chain and critical supplier mapping
Phase 2 (month 3-4): Policies and procedures
- Risk management policy development
- Incident reporting procedures (24h/72h/30d)
- Production business continuity plan
Phase 3 (month 5-8): Technical implementation
- IT/OT network segmentation
- SOC deployment (internal or SOC as a Service)
- EDR on endpoints, SIEM for logs, OT monitoring
Phase 4 (month 9-12): Testing and improvement
- Infrastructure penetration testing
- Incident response exercises
- Compliance audit before NIS2 deadline
Cybersecurity for Your Industry
Learn more about cybersecurity in your industry:
Why this matters for organizations
NIS2 directive imposes new cybersecurity obligations on pharmaceutical companies. Check requirements, deadlines, and implementation plan. In the context of growing cyber threats and tightening regulations (NIS2, DORA), organizations must proactively manage this security area. Failure to implement adequate safeguards can lead to data breaches, financial penalties, and reputational damage.
Best practices for implementation
Effective implementation requires several key steps:
- Risk assessment and inventory — identify assets, threats, and vulnerabilities specific to your organization.
- Policy development — document requirements, roles, and responsibilities.
- Technical controls — deploy tools and configurations proportionate to identified risks.
- Training and awareness — engage employees in protecting organizational security.
- Monitoring and continuous improvement — regularly verify effectiveness and adapt to the evolving threat landscape.
Related topics
See also:
- NIS2 for hospitals — implementation and funding
- Security Audit Pricing Calculator
- NIS2 for hospitals — compliance
